What do we know about the adaptive immune response to covid-19?
Article explores the role of adaptive immunity, its B and T lymphocytes components, the duration of adaptive immunity to SARS-CoV-2; the effect of Covid vaccines and new variants and how the adaptive immune response to Covid-19 compares with influenza and other coronaviruses. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - January 31, 2023 Category: Consumer Health News Source Type: news

Healthcare Experts See Links Between COVID-19 and RSV as Tripledemic Pressures Ease on Hospitals and Clinical Laboratories
Some medical experts suggest an ‘immunity gap’ related to COVID-19 mitigation measures, while others point to alternative theories Surge in fall/winter SARS-CoV-2, influenza (flu), and respiratory syncytial virus (RSV) hospitalizations and ensuing clinical laboratory test referrals—dubbed by some public health experts as a “tripledemic”—appear to have eased in the US, according to stats from the […] The post <strong>Healthcare Experts See Links Between COVID-19 and RSV as Tripledemic Pressures Ease on Hospitals and Clinical Laboratories</strong> appeared first on Dark Daily. (Source: Dark Daily)
Source: Dark Daily - January 30, 2023 Category: Laboratory Medicine Authors: Jillia Schlingman Tags: Laboratory News Laboratory Pathology Laboratory Resources Laboratory Testing anatomic pathology Asuncion Mejias MD PhD Becker’s Hospital Review Boston Globe CDC Center for Vaccines and Immunity centers for disease control and prevent Source Type: news

FDA Experts Vote to Make All COVID-19 Vaccines and Boosters Bivalent
In a unanimous decision, all 21 voting members of the U.S. Food and Drug Administration’s (FDA) vaccine committee recommended that the U.S. start using the same COVID-19 virus strain in all of the COVID-19 vaccines, including primary and booster doses. That means the bivalent booster dose, which targets both the original SARS-CoV-2 strain and the Omicron BA.4/5 strains, would soon become the only type used for all primary shots and boosters. The decision reflects a turning point in the pandemic. Until now, vaccine makers have tried to keep up with constantly evolving variants, but they’ve always been a few step...
Source: TIME: Health - January 27, 2023 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 healthscienceclimate Source Type: news

U.S. FDA proposes shift to annual COVID vaccine shots
The U.S. health regulator on Monday proposed one dose of the latest updated COVID-19 shot annually for healthy adults, similar to the influenza immunization campaign, as it aims to simplify the country's COVID-vaccine strategy. The U.S. Food and Drug Administration also asked its panel of external…#fda #pfizerinc #omicron (Source: Reuters: Health)
Source: Reuters: Health - January 23, 2023 Category: Consumer Health News Source Type: news

F.D.A. Outlines a Plan for Annual Covid Boosters
In advance of a scientific meeting on Thursday, officials proposed offering new shots to Americans each fall, a strategy long employed against the flu. (Source: NYT Health)
Source: NYT Health - January 23, 2023 Category: Consumer Health News Authors: Apoorva Mandavilli Tags: your-feed-science Vaccination and Immunization Coronavirus (2019-nCoV) Coronavirus Omicron Variant Immune System Food and Drug Administration Influenza Disease Rates United States Source Type: news

Flu Hospitalizations and Vaccine Coverage by Race and Ethnicity Flu Hospitalizations and Vaccine Coverage by Race and Ethnicity
This CDC report reveals that racial and ethnic disparities in influenza vaccination coverage and access to care have persisted since the 2009-11 influenza seasons.Morbidity & Mortality Weekly Report (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 20, 2023 Category: Consumer Health News Tags: Public Health & Prevention Journal Article Source Type: news

It ’ s Not Just You: The Flu Is Bad This Year
This winter has brought a cold reminder that SARS-CoV-2 isn’t the only virus we need to think about. After two winters during which influenza was subdued by pandemic precautions, the last few months have shown that the flu is still a major public health threat that can overwhelm busy hospitals and cost thousands of lives. This flu season is no 100-year outbreak. But it’s the most severe flu season since the start of the pandemic. “It looks very similar to some of the worst seasons in the past 10 years,” says John Huddleston, a staff scientist in the Bedford Lab at Fred Hutch Medical Center, where he...
Source: TIME: Health - January 19, 2023 Category: Consumer Health News Authors: Tara Law Tags: Uncategorized healthscienceclimate Source Type: news

Moderna ’ s mRNA-Based RSV Vaccine Just Passed a Major Test
Moderna has become a well-known name thanks to its highly effective COVID-19 vaccine, based on mRNA technology. But even before the pandemic hit, the company was developing an mRNA-based vaccine against another scourge, respiratory syncytial virus (RSV), which primarily affects infants and the elderly. In a release issued on Jan. 17, the Massachusetts-based company said an early look at data from the late-stage trial of its RSV vaccine shows that the shot is effective. Among 37,000 people over age 60 in 22 countries, the vaccine was 83.7% effective in reducing moderate RSV illness, defined as two or more symptoms of the di...
Source: TIME: Health - January 18, 2023 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 healthscienceclimate Technology Source Type: news

Rwanda: Health Official Dispels Myths Around Recent Bout of Flu
[New Times] The bout of influenza that affected a lot of people towards the end of 2022 and the New Year has nothing to do with the Covid-19 virus and nor is it in any way related to vaccination. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - January 13, 2023 Category: African Health Source Type: news

Novavax says COVID vaccines will be much like annual flu shots
SINGAPORE -- Future sales of COVID-19 vaccines will take place in "an annual vaccination market, a lot like influenza," according to Novavax's executive vice president. The U.S.-based biotechnology company, which gained U.S. authorization for its vaccine last summer, produces its jabs in…#takedapharmaceutical #novavax #singapore (Source: Reuters: Health)
Source: Reuters: Health - January 13, 2023 Category: Consumer Health News Source Type: news

Roche announces the European Commission approval of Xofluza for the treatment and prevention of influenza in children aged one year and above
Xofluza is now approved in the EU for the treatment of uncomplicated influenza and for post-exposure prophylaxis of influenza in children aged one year and above, and in adolescents and adultsXofluza is the first influenza antiviral with a new mechanism of action in almost 20 years, stopping viral replication faster thanoseltamivirSingle-doseXofluza helps reduce the societal burden of influenza by helping patients recover quickly and by preventing infection in individuals following contact with someone with the virusBasel, 12 January 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission (EC...
Source: Roche Investor Update - January 12, 2023 Category: Pharmaceuticals Source Type: news

Roche announces the European Commission approval of Xofluza for the treatment and prevention of influenza in children aged one year and above
Xofluza is now approved in the EU for the treatment of uncomplicated influenza and for post-exposure prophylaxis of influenza in children aged one year and above, and in adolescents and adultsXofluza is the first influenza antiviral with a new mechanism of action in almost 20 years, stopping viral replication faster thanoseltamivirSingle-doseXofluza helps reduce the societal burden of influenza by helping patients recover quickly and by preventing infection in individuals following contact with someone with the virusBasel, 12 January 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission (EC...
Source: Roche Media News - January 12, 2023 Category: Pharmaceuticals Source Type: news

Seasonal influenza vaccine uptake (GP patient survey) data collection
Details for the influenza vaccine uptake data collection (GP patient survey) from GP practices for the 2022 to 2023 flu season. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - January 9, 2023 Category: Consumer Health News Source Type: news

Flu Vaccine 36 Percent Effective Against A(H3N2) in 2021/2022
TUESDAY, Jan. 3, 2023 -- For the 2021 to 2022 influenza season, influenza vaccines were 36 percent effective against influenza A(H3N2)-related illnesses, according to a study published online Dec. 12 in Clinical Infectious Diseases. Ashley M. Price,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 3, 2023 Category: Pharmaceuticals Source Type: news

Researchers make important progress toward a possible universal flu vaccine
Influenza is continuing its early and severe rampage through the United States, but there's some hopeful news for flu seasons of the future. (Source: CNN.com - Health)
Source: CNN.com - Health - December 22, 2022 Category: Consumer Health News Source Type: news